Hospital Ramón y Cajal -ko ikertzaileekin lankidetzan egindako argitalpenak (215)

2024

  1. COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis

    Frontiers in immunology, Vol. 15, pp. 1439393

  2. Clot migration in patients treated with tenecteplase versus alteplase before mechanical thrombectomy

    European Stroke Journal

  3. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis

    Frontiers in Immunology, Vol. 15

  4. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes

    Stroke, Vol. 55, Núm. 2, pp. 392-402

  5. Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults

    International Journal of Molecular Sciences, Vol. 25, Núm. 14

  6. Hemorrhagic Transformation in Noncardioembolic Acute Ischemic Stroke: MRI Analysis from PACIFIC-STROKE

    Stroke, Vol. 55, Núm. 6, pp. 1477-1488

  7. Outcomes of Decompressive Surgery for Patients With Severe Cerebral Venous Thrombosis: DECOMPRESS2 Observational Study

    Stroke, Vol. 55, Núm. 5, pp. 1218-1226

  8. Passive assessment of tapping speed through smartphone is useful for monitoring multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 86

  9. Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study

    Multiple Sclerosis Journal, Vol. 30, Núm. 10, pp. 1341-1349

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Association of Serum Neurofilament Light Chain Levels at Disease Onset with Disability Worsening in Patients with a First Demyelinating Multiple Sclerosis Event Not Treated with High-Efficacy Drugs

    JAMA Neurology, Vol. 80, Núm. 4, pp. 397-403

  3. Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine

    Vaccines, Vol. 11, Núm. 9

  4. Development of Pharmacological Strategies with Therapeutic Potential in Ischemic Stroke

    Antioxidants, Vol. 12, Núm. 12

  5. Dihydropyrimidinase-Related Protein 2 Is a New Partner in the Binding between 4E-BP2 and eIF4E Related to Neuronal Death after Cerebral Ischemia

    International Journal of Molecular Sciences, Vol. 24, Núm. 9

  6. Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis

    Frontiers in Immunology, Vol. 14

  7. Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: A national multicentre observational study

    Journal of Neurology, Neurosurgery and Psychiatry

  8. Genetic Architecture of Ischaemic Strokes after COVID-19 Shows Similarities with Large Vessel Strokes

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

  9. Mechanical thrombectomy beyond 6 hours in acute ischaemic stroke with large vessel occlusion in the carotid artery territory: Experience at a tertiary hospital

    Neurologia, Vol. 38, Núm. 4, pp. 236-245

  10. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

  11. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788